• 1
    Ikoma A, Steinhoff M, Ständer S, Yosipovitch G, Schmelz M. The neurobiology of itch. Nat Rev Neurosci 2006: 7: 535547.
  • 2
    Ständer S, Streit M, Darsow U et al. Diagnostic and therapeutic procedures in chronic pruritus. J Dtsch Dermatol Ges 2006: 4: 350370.
  • 3
    Ständer S, Weisshaar E, Mettang T et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Dermatol Venerol 2007: 87: 291294.
  • 4
    Twycross R, Greaves MW, Handwerker H et al. Itch: scratching more than the surface. QJM 2003: 96: 726.
  • 5
    Ständer S. Rational symptomatic therapy for chronic pruritus. Hautarzt 2006: 57: 403410.
  • 6
    Ständer S, Schmelz M. Chronic itch and pain – similarities and differences. Eur J Pain 2006: 10: 473478.
  • 7
    Bromm B, Scharein E, Darsow U, Ring J. Effects of menthol and cold on histamine-induced itch and skin reactions in man. Neurosci Lett 1995: 187: 157160.
  • 8
    Peier AM, Moqrich A, Hergarden AC et al. A TRP channel that senses cold stimuli and menthol. Cell 2002: 108: 705715.
  • 9
    Story GM, Peier AM, Reeve AJ et al. ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 2003: 112: 819829.
  • 10
    Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997: 389: 816824.
  • 11
    Zygmunt PM, Petersson J, Andersson DA et al. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 1999: 400: 452457.
  • 12
    Jessell TM, Iversen LL, Cuello AC. Capsaicin-induced depletion of substance P from primary sensory neurones. Brain Res 1978: 152: 183.
  • 13
    Ständer S, Luger T, Metze D. Treatment of prurigo nodularis with topical capsaicin. J Am Acad Dermatol 2001: 44: 471478.
  • 14
    Ständer S, Schmelz M, Metze D, Luger T, Rukwied R. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 2005: 38: 177188.
  • 15
    Dvorak M, Watkinson A, McGlone F, Rukwied R. Histamine induced responses are attenuated by a cannabinoid receptor agonist in human skin. Inflamm Res 2003: 52: 238245.
  • 16
    Rukwied R, Watkinson A, McGlone F, Dvorak M. Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 2003: 102: 283288.
  • 17
    Amaya F, Shimosato G, Kawasaki Y et al. Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 2006: 124: 175183.
  • 18
    Farquhar-Smith WP, Rice AS. A novel neuroimmune mechanism in cannabinoid-mediated attenuation of nerve growth factor-induced hyperalgesia. Anesthesiology 2003: 99: 13911401.
  • 19
    Szepietowski JC, Reich A, Szepietowski T. Emollients with endocannabinoids in the treatment of uremic pruritus: discussion of the therapeutic options. Ther Apher Dial 2005: 9: 277279.
  • 20
    Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005: 13: 97103.
  • 21
    Ständer S, Reinhardt HW, Luger TA. Topical cannabinoid agonists. An effective new possibility for treating chronic pruritus. Hautarzt 2006: 57: 801807.
  • 22
    Patwardhan AM, Jeske NA, Price TJ et al. The cannabinoid WIN 55,212-2 inhibits transient receptor potential vanilloid 1 (TRPV1) and evokes peripheral antihyperalgesia via calcineurin. Proc Natl Acad Sci U S A 2006: 103: 1139311398.
  • 23
    Fattore L, Cossu G, Spano MS et al. Cannabinoids and reward: interactions with the opioid system. Crit Rev Neurobiol 2004: 16: 147158.
  • 24
    Vigano D, Rubino T, Parolaro D. Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 2005: 81: 360368.
  • 25
    Ibrahim MM, Porreca F, Lai J et al. CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A 2005: 102: 30933098.
  • 26
    Senba E, Katanosaka K, Yajima H, Mizumura K. The immunosuppressant FK506 activates capsaicin- and bradykinin-sensitive DRG neurons and cutaneous C-fibers. Neurosci Res 2004: 50: 257262.
  • 27
    Ständer S, Ständer H, Seeliger S, Luger TA, Steinhoff M. Topical pimecrolimus (SDZ ASM 981) and tacrolimus (FK 506) transiently induces neuropeptide release and mast cell degranulation in murine skin. Br J Dermatol 2007: 156: 10201026.
  • 28
    Ständer S, Schürmeyer-Horst F, Luger TA, Weisshaar E. Treatment of pruritic diseases with topical calcineurin inhibitors. Therapeut Clin Risk Management 2006: 2: 213218.
  • 29
    Hill SJ. Distribution, properties, and functional characteristics of three classes of histamine receptor. Pharmacol Rev 1990: 42: 4583.
  • 30
    Gelfand EW, Appajosyula S, Meeves S. Anti-inflammatory activity of H1-receptor antagonists: review of recent experimental research. Curr Med Res Opin 2004: 20: 7381.
  • 31
    Andoh T, Kuraishi Y. Inhibitory effects of azelastine on substance P-induced itch-associated response in mice. Eur J Pharmacol 2002: 436: 235239.
  • 32
    Amsellem C, Czarlewski W, Lagarde M, Pacheco Y. Inhibitory effect of loratadine on leukotriene B4 production by neutrophils either alone or during interaction with human airway epithelial cells. Pulm Pharmacol Ther 1998: 11: 245252.
  • 33
    Schroeder JT, Schleimer RP, Lichtenstein LM, Kreutner W. Inhibition of cytokine generation and mediator release by human basophils treated with desloratadine. Clin Exp Allergy 2001: 31: 13691377.
  • 34
    Lippert U, Kruger-Krasagakes S, Moller A, Kiessling U, Czarnetzki BM. Pharmacological modulation of IL-6 and IL-8 secretion by the H1-antagonist decarboethoxy-loratadine and dexamethasone by human mast and basophilic cell lines. Exp Dermatol 1995: 4: 272276.
  • 35
    Wu P, Mitchell S, Walsh GM. A new antihistamine levocetirizine inhibits eosinophil adhesion to vascular cell adhesion molecule-1 under flow conditions. Clin Exp Allergy 2005: 35: 10731079.
  • 36
    Giustizieri ML, Albanesi C, Fluhr J, Gisondi P, Norgauer J, Girolomoni G. H1 histamine receptor mediates inflammatory responses in human keratinocytes. J Allergy Clin Immunol 2004: 114: 11761182.
  • 37
    Vancheri C, Mastruzzo C, Tomaselli V et al. The effect of fexofenadine on expression of intercellular adhesion molecule 1 and induction of apoptosis on peripheral eosinophils. Allergy Asthma Proc 2005: 26: 292298.
  • 38
    Gillard M, Chatelain P. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol 2006: 530: 205214.
  • 39
    Bell JK, McQueen DS, Rees JL. Involvement of histamine H4 and H1 receptors in scratching induced by histamine receptor agonists in Balb C mice. Br J Pharmacol 2004: 142: 374380.
  • 40
    Aymard JP, Lederlin P, Witz F et al. Cimetidine for pruritus in Hodgkin′s disease. Br Med J 1980: 280: 151152.
  • 41
    Weick JK, Donovan PB, Najean Y et al. The use of cimetidine for the treatment of pruriuts in polycythaemia vera. Arch Int med 1982: 142: 241242.
  • 42
    Andoh T, Kuraishi Y. Intradermal leukotriene B4, but not prostaglandin E2, induces itch-associated responses in mice. Eur J Pharmacol 1998: 353: 9396.
  • 43
    Miyoshi M, Sakurai T, Kodama S. Clinical evaluation of urinary leukotriene E4 levels in children with atopic dermatitis. Arerugi 1999: 48: 11481152.
  • 44
    Di Lorenzo G, Pacor ML, Mansueto P et al. Is there a role for antileukotrienes in urticaria? Clin Exp Dermatol 2006: 31: 327334.
  • 45
    Bernardini N, Roza C, Sauer SK, Gomeza J, Wess J, Reeh PW. Muscarinic M2 receptors on peripheral nerve endings: a molecular target of antinociception. J Neurosci 2002: 22: RC229.
  • 46
    Carucci JA, Washenik K, Weinstein A, Shupack J, Cohen DE. The leukotriene antagonist zafirlukast as a therapeutic agent for atopic dermatitis. Arch Dermatol 1998: 134: 785786.
  • 47
    Woodmansee DP, Simon RA. A pilot study examining the role of zileuton in atopic dermatitis. Ann Allergy Asthma Immunol 1999: 83: 548552.
  • 48
    Zabawski EJ Jr, Kahn MA, Gregg LJ. Treatment of atopic dermatitis with zafirlukast. Dermatol Online J 1999: 5: 10.
  • 49
    Takaoka A, Arai I, Sugimoto M et al. Involvement of IL-31 on scratching behavior in NC/Nga mice with atopic-like dermatitis. Exp Dermatol 2006: 15: 161167.
  • 50
    Schulz F, Marenholz I, Fölster-Holst R et al. A common haplotype of the IL-31 gene influencing gene expression is associated with nonatopic eczema. J Allergy Clin Immunol 2007: 120: 10971102.
  • 51
    Neis MM, Peters B, Dreuw A et al. Enhanced expression levels of IL-31 correlate with IL-4 and IL-13 in atopic and allergic contact dermatitis. J Allergy Clin Immunol 2006: 118: 930937.
  • 52
    Gaspari AA, Lotze MT, Rosenberg SA, Stern JB, Katz SI. Dermatologic changes associated with interleukin 2 administration. JAMA 1987: 258: 16241629.
  • 53
    Darsow U, Scharein E, Bromm B, Ring J. Skin testing of the pruritogenic activity of histamine and cytokines (interleukin-2 and tumour necrosis factor-alpha) at the dermal-epidermal junction. Br J Dermatol 1997: 137: 415417.
  • 54
    Martin HA, Murphy PR. Interleukin-2 activates a sub-population of cutaneous C-fibre polymodal nociceptors in the rat hairy skin. Arch Physiol Biochem 1995: 103: 136148.
  • 55
    Martin HA. Bradykinin potentiates the chemoresponsiveness of rat cutaneous C-fibre polymodal nociceptors to interleukin-2. Arch Physiol Biochem 1996: 104: 229238.
  • 56
    Wahlgren CF, Scheynius A, Hagermark O. Antipruritic effect of oral cyclosporin A in atopic dermatitis. Acta Derm Venereol 1990: 70: 323329.
  • 57
    Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001: 4: 7277.
  • 58
    Jinks SL, Carstens E. Superficial dorsal horn neurons identified by intracutaneous histamine: chemonociceptive responses and modulation by morphine. J Neurophysiol 2000: 84: 616627.
  • 59
    Drzezga A, Darsow U, Treede RD et al. Central activation by histamine-induced itch: analogies to pain processing: a correlational analysis of O-15 H2O positron emission tomography studies. Pain 2001: 92: 295305.
  • 60
    Sun YG, Chen ZF. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature 2007: 448: 700703.
  • 61
    Manenti L, Vaglio A. Gabapentin for uraemic pruritus. Nephrol Dial Transplant 2005: 20: 12781279.
  • 62
    Yesudian PD, Wilson NJ. Efficacy of gabapentin in the management of pruritus of unknown origin. Arch Dermatol 2005: 141: 15071509.
  • 63
    Schürmeyer-Horst F, Fischbach R, Nabavi D, Metze D, Ständer S. Brachioradial pruritus: a rare, localized, neuropathic form of itching. Hautarzt 2006: 57: 523527.
  • 64
    Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004: 45 (Suppl 6): 1318.
  • 65
    Wedekind D, Bandelow B. The alpha2delta subunit of the voltage-dependent calcium channel. A new pharmaceutical target for psychiatry and neurology. Nervenarzt 2005: 76: 888891.
  • 66
    Metze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999: 41: 533539.
  • 67
    Metze D, Reimann S, Luger TA. Effective treatment of pruritus with naltrexone, an orally active opiate antagonist. Ann N Y Acad Sci 1999: 885: 430432.
  • 68
    Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999: 41: 431434.
  • 69
    Mansour-Ghanaei F, Taheri A, Froutan H et al. Effect of oral naltrexone on pruritus in cholestatic patients. World J Gastroenterol 2006: 12: 11251128.
  • 70
    Monroe EW. Efficacy and safety of nalmefene in patients with severe pruritus caused by chronic urticaria and atopic dermatitis. J Am Acad Dermatol 1989: 21: 135136.
  • 71
    Brune A, Metze D, Luger TA, Ständer S. Antipruritic therapy with the oral opioid receptor antagonist naltrexone. Open, non-placebo controlled administration in 133 patients. Hautarzt 2004: 55: 11301136.
  • 72
    Tefferi A, Fonseca R. Selective serotonin reuptake inhibitors are effective in the treatment of polycythemia vera-associated pruritus. Blood 2002: 99: 2627.
  • 73
    Zylicz Z, Krajnik M, Sorge AA, Costantini M. Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial. J Pain Symptom Manage 2003: 26: 11051112.
  • 74
    Zylicz Z, Smits C, Krajnik M. Paroxetine for pruritus in advanced cancer. J Pain Symptom Manage 1998: 16: 121124.
  • 75
    Duman EN, Kesim M, Kadioglu M, Yaris E, Kalyoncu NI, Erciyes N. Possible involvement of opioidergic and serotonergic mechanisms in antinociceptive effect of paroxetine in acute pain. J Pharmacol Sci 2004: 94: 161165.
  • 76
    Muller C, Pongratz S, Pidlich J et al. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998: 10: 865870.
  • 77
    Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995: 61: 3337.
  • 78
    Weisshaar E, Dunker N, Domrose U, Neumann KH, Gollnick H. Plasma serotonin and histamine levels in hemodialysis-related pruritus are not significantly influenced by 5-HT3 receptor blocker and antihistaminic therapy. Clin Nephrol 2003: 59: 124129.
  • 79
    Zhang X, Huang J, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005: 24: 42114223.
  • 80
    Johansson O, Liang Y, Emtestam L. Increased nerve growth factor- and tyrosine kinase A-like immunoreactivities in prurigo nodularis skin – an exploration of the cause of neurohyperplasia. Arch Dermatol Res 2002: 293: 614619.
  • 81
    Toyoda M, Nakamura M, Makino T, Hino T, Kagoura M, Morohashi M. Nerve growth factor and substance P are useful plasma markers of disease activity in atopic dermatitis. Br J Dermatol 2002: 147: 7179.
  • 82
    Steinhoff M, Neisius U, Ikoma A et al. Proteinase-activated receptor-2 mediates itch: a novel pathway for pruritus in human skin. J Neurosci 2003: 23: 61766180.
  • 83
    Obreja O, Rukwied R, Steinhoff M, Schmelz M. Neurogenic components of trypsin- and thrombin-induced inflammation in rat skin, in vivo. Exp Dermatol 2006: 15: 5865.
  • 84
    Ui H, Andoh T, Lee JB, Nojima H, Kuraishi Y. Potent pruritogenic action of tryptase mediated by PAR-2 receptor and its involvement in anti-pruritic effect of nafamostat mesilate in mice. Eur J Pharmacol 2006: 530: 172178.
  • 85
    Steinhoff M, Vergnolle N, Young SH et al. Agonists of proteinase-activated receptor 2 induce inflammation by a neurogenic mechanism. Nat Med 2000: 6: 151158.